What is the appropriate management of coronary vasospasm?

Management of Coronary Vasospasm

Calcium channel blockers at high doses (verapamil 240-480 mg/day, diltiazem 180-360 mg/day, or nifedipine 60-120 mg/day) are the first-line treatment for coronary vasospasm, with long-acting nitrates added as second-line therapy for refractory symptoms. 1, 2, 1

Immediate Management

Acute Episodes

• Sublingual nitroglycerin provides rapid relief of acute vasospastic episodes and should be prescribed to all patients with appropriate instructions 3, 1
• For catheter-induced spasm during angiography, administer 0.3 mg intracoronary nitroglycerin directly into the affected vessel 1, 2
• Acute episodes typically resolve within minutes with nitrate administration

Essential Lifestyle Modifications

• Smoking cessation is mandatory - this is the most consistently associated modifiable risk factor 1, 2, 4
• Remove other precipitating factors including emotional stress triggers

Pharmacological Treatment Algorithm

First-Line: Calcium Channel Blockers

Start with a single calcium channel blocker at moderate to high doses 1, 2, 5, 6:

• Verapamil 240-480 mg daily
• Diltiazem 180-360 mg daily
• Nifedipine 60-120 mg daily

Important caveat: Calcium antagonists achieve complete symptom resolution in only 38% of patients as monotherapy 3. Therefore, most patients will require combination therapy.

Second-Line: Add Long-Acting Nitrates

If symptoms persist despite optimized calcium channel blocker dosing, add long-acting nitrates 3, 1, 2:

• Isosorbide mononitrate 10 mg BID, uptitrated as needed
• Critical consideration: Ensure a nitrate-free interval each day (typically 10-12 hours) to prevent tolerance 3
• While nitrates are highly effective for acute vasospasm, they are less successful at preventing resting angina attacks 3

Third-Line: Combination Strategies for Refractory Disease

For patients with very active disease not controlled on single-agent therapy 1, 2, 5:

• Combine nitrates with calcium channel blockers of different classes (e.g., dihydropyridine with verapamil or diltiazem)
• Consider switching from nitrate to nicorandil (5 mg BID, uptitrated) where available - this potassium channel activator may be useful in refractory cases 3, 5, 7
• Alpha-receptor blockers have shown occasional benefit, particularly in patients not responding completely to calcium channel blockers and nitrates 1, 2

Important Contraindications and Cautions

Beta-Blockers: Use with Extreme Caution

Beta-blockers have theoretical adverse potential in vasospastic angina and their clinical effect is controversial 1, 2. The concern is that unopposed alpha-adrenergic stimulation may worsen coronary spasm. They should generally be avoided unless there is a compelling indication (e.g., post-MI with LV dysfunction).

Aspirin Considerations

The role of aspirin in isolated vasospastic angina is controversial 3. However, if there is coexisting atherosclerotic disease or endothelial dysfunction, aspirin and statin therapy should be considered 5, 7.

Risk Stratification and Prognosis-Based Management

Favorable Prognosis Group

Patients with normal or near-normal coronary arteries have excellent prognosis:

• 89-97% five-year survival rate 1, 2
• 3.6% incidence of sudden death over 7 years
• 6.5% incidence of MI over 7 years

Key management point: In approximately 50% of patients, spontaneous remission occurs after at least 1 year of medical treatment. Therefore, it is acceptable to taper and discontinue treatment 6-12 months after angina has disappeared 3.

High-Risk Features Requiring Aggressive Management

Patients with vasospasm superimposed on obstructive coronary disease have worse prognosis:

• 95% five-year survival with normal arteries or single-vessel disease
• 80% five-year survival with multivessel disease 1, 2

For these patients:

• Maintain aggressive vasodilator therapy
• Follow guideline-directed medical therapy for atherosclerotic disease (statin, ACE inhibitor, antiplatelet therapy) 3, 4
• Consider revascularization for significant fixed lesions

Management of Life-Threatening Complications

Arrhythmias

Vasospastic angina can cause:

• Ventricular tachycardia/fibrillation
• High-degree AV block
• Syncope

Device therapy considerations 1, 2:

• ICD implantation should be considered for patients with documented life-threatening ventricular arrhythmias
• Pacemaker implantation for transient AV block if recurrent despite optimal medical therapy
• Wearable cardiac defibrillator can be used in high-risk patients during optimization of medical therapy 8

Refractory Cases

For the occasional patient refractory to standard medications 1, 2, 9:

• Rho-kinase inhibitor fasudil (where available)
• Anti-adrenergic drugs
• Neural therapies (cardiac denervation has shown marginal benefit)
• Corticosteroids in cases of presumed inflammatory etiology 8
• Percutaneous coronary intervention is generally not indicated for vasospasm alone

Diagnostic Confirmation

Before initiating long-term therapy, confirm the diagnosis through:

• Documentation of transient ST-segment elevation during chest pain episodes
• Provocative testing with acetylcholine or ergonovine during coronary angiography (when diagnosis is uncertain) 1, 2
• Withdraw nitrates and calcium channel blockers well before provocative testing

Critical safety note: Provocative testing should be avoided in patients with significant left main disease, advanced three-vessel disease, high-grade obstructive lesions, or significant LV dysfunction 4.

Contemporary Approach to INOCA/ANOCA

The 2023 AHA/ACC guidelines provide a comprehensive framework for invasive coronary functional testing to identify specific endotypes 5, 7:

• Epicardial vasospasm: >90% diameter reduction with acetylcholine plus symptoms and ST changes
• Microvascular spasm: Angina with ST changes but <90% epicardial constriction
• This phenotyping allows targeted therapy selection